Skip to main content
All Guides

Depression Care · Clinical Deep Dive

What STAR*D Taught Us About Sequenced Antidepressant Trials—and When to Pivot to Interventional Psychiatry

Reviewing remission decay across sequential oral antidepressant steps and the clinical rationale for moving to TMS or SPRAVATO® after two adequate trials.

Modal Mental HealthPublished · Updated 7 min read

The clinical reality of sequential antidepressant trials

The NIMH-funded Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial remains one of the largest real-world examinations of outpatient depression care ever conducted. Its central lesson is sobering yet clarifying: while roughly one-third of patients achieve remission on their first well-dosed SSRI, likelihood of remission drops sharply with each subsequent oral medication switch or augmentation.

By the third and fourth sequential medication steps, remission rates fall into the low teens while cumulative side-effect burden—fatigue, emotional blunting, weight shifts, and sexual dysfunction—continues to rise. Continuing to cycle through mechanistically similar pills often costs patients months or years of avoidable morbidity.

Defining Treatment-Resistant Depression (TRD) as a clinical inflection point

In clinical psychiatry and insurance medical-necessity criteria, Treatment-Resistant Depression (TRD) is generally defined as an inadequate response to at least two antidepressant trials of adequate dose and duration within the current depressive episode.

Rather than viewing TRD as a prognostic dead end, modern interventional psychiatry treats it as an inflection point: the moment to introduce a distinct biological mechanism—either targeted electromagnetic neuromodulation (TMS) or glutamatergic modulation (SPRAVATO®)—while optimizing foundational medication and psychotherapy.

  • Step 1–2: Thorough diagnostic confirmation (ruling out bipolar spectrum, thyroid/metabolic contributors, or occult sleep apnea)
  • After 2+ inadequate trials: Insurance criteria for TMS or SPRAVATO® are typically met
  • Collaborative care: Interventional treatments layer seamlessly onto ongoing psychotherapy and primary care

Choosing between neuromodulation, glutamate therapy, and psychopharmacology

At Modal Mental Health, Dr. Taner Aydin evaluates each patient's prior medication history, symptom profile (such as anxious distress, anhedonia, or OCD comorbidity), and daily logistics—either in person or via New York Virtual Care.

Patients who prefer a drug-free, non-sedating intervention with immediate driving clearance frequently gravitate toward TMS, whereas those seeking a rapid glutamate-pathway option who can accommodate a 2-hour REMS suite visit and ride home may consider SPRAVATO®.

Common Questions

Most commercial New York insurance plans, Medicare, and Medicaid consider interventional options after two or more adequate antidepressant trials have not provided sufficient relief, though exact criteria vary by plan. Our team verifies your benefits in 1–2 business days.

More Patient Guides

All guides